SCHEMBL892449

SCHEMBL892449

CCOC(=O)c1cc(Cc2cc(F)ccc2F)on1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.45
DPP4 P27487 2/20 0.42
NPC1 O15118 2/20 0.42
TSHR P16473 2/20 0.41
THRB P10828 2/20 0.41
L3MBTL1 Q9Y468 3/20 0.40
MAPT P10636 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPK1 P28482 2/20 0.40
DPP8 Q6V1X1 1/20 0.40
TP53 P04637 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15932174 0.86 L3MBTL1 (0.41) RAB9ANPC1L3MBTL1MAPTALDH1A1
SCHEMBL15932033 0.86 SLC26A6 (0.47) RAB9ANPC1TSHRL3MBTL1MAPT
SCHEMBL15932198 0.86 THRB (0.51) RAB9ATHRBL3MBTL1MAPTALDH1A1
SCHEMBL892112 0.82 SLC26A6 (0.49) RAB9ANPC1THRBL3MBTL1MAPT
SCHEMBL15932313 0.82 MAPT (0.44) RAB9ANPC1THRBL3MBTL1MAPT
SCHEMBL20020127 0.82 L3MBTL1 (0.39) RAB9ANPC1L3MBTL1MAPTALDH1A1
SCHEMBL15932066 0.82 MAPT (0.43) RAB9ATSHRTHRBL3MBTL1MAPT
SCHEMBL892745 0.81 SMN1; SMN2 (0.43) RAB9ADPP4NPC1THRBL3MBTL1
SCHEMBL15932075 0.80 SLC26A6 (0.47) TSHRTHRBMAPTALDH1A1MAPK1
SCHEMBL892948 0.78 SLC26A6 (0.43) DPP4TSHRTHRBALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12178805-B2 Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders REMYND N.V. (BE) 2024-12-31 US disclosed
US-11939324-B2 Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders REMYND N.V. (BE) 2024-03-26 US disclosed
EP-3621963-B1 COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS REMYND N V (BE) 2024-01-24 EP disclosed
CN-110650955-B Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders 瑞敏德股份有限公司 2023-07-25 CN disclosed
US-20230099111-A1 COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-03-30 US disclosed
US-11548881-B2 Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders REMYND N.V. (BE) 2023-01-10 US disclosed
US-11548881-B2 Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders REMYND N.V. (BE) 2023-01-10 US disclosed
US-20200253934-A1 INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2020-08-13 US disclosed
EP-3634407-A1 INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS Remynd N.V. (BE) 2020-04-15 EP disclosed
US-20200095238-A1 COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS CISTIM (BE) 2020-03-26 US disclosed
US-10117850-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2018-11-06 US disclosed
EP-3190109-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven (BE) 2017-07-12 EP disclosed
EP-2440550-B1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES UNIV LEUVEN KATH (BE) 2017-03-15 EP disclosed
US-20160324828-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2016-11-10 US disclosed
US-9434722-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2016-09-06 US disclosed
US-20140066457-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2014-03-06 US disclosed
US-8618138-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2013-12-31 US disclosed
EP-2440550-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2012-04-18 EP disclosed
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-04-05 US disclosed
WO-2010142801-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN RAB9A 1779/4885DPP4 1744/4885NPC1 704/4885
US-20200095238-A1 COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS MAPT, PSEN1, PSEN2 RAB9A 1661/4885DPP4 2295/4885NPC1 195/4885
US-20140066457-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN RAB9A 1770/4885DPP4 1787/4885NPC1 651/4885
US-20160324828-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN RAB9A 1770/4885DPP4 1787/4885NPC1 651/4885
US-10117850-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases SNCA, MAPT, NLN RAB9A 1770/4885DPP4 1787/4885NPC1 651/4885
US-12178805-B2 Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders PDE4A, PDE12, PDE2A RAB9A 853/4885DPP4 364/4885NPC1 603/4885
US-20230099111-A1 COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS MAPT, PSEN1, PSEN2 RAB9A 1661/4885DPP4 2295/4885NPC1 195/4885
US-11548881-B2 Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders MAPT, PSEN1, PSEN2 RAB9A 1661/4885DPP4 2295/4885NPC1 195/4885
US-20200253934-A1 INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS PDE4A, PDE12, PDE2A RAB9A 853/4885DPP4 364/4885NPC1 603/4885
US-11939324-B2 Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders MAPT, PSEN1, PSEN2 RAB9A 1661/4885DPP4 2295/4885NPC1 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.